HAART treatment with free provided medications for people living with HIV in Huzhou, China

IF 1.6 Q4 INFECTIOUS DISEASES

Journal of clinical virology plus Pub Date : 2024-09-20 DOI:10.1016/j.jcvp.2024.100191

Xiaofeng Li , Zhaowei Tong , Qingqiu Zeng , Meiling Xu , Bin Shen , Wei Zhang , Yan Zhang , Weihong Wang , Kefeng Qin

{"title":"HAART treatment with free provided medications for people living with HIV in Huzhou, China","authors":"Xiaofeng Li , Zhaowei Tong , Qingqiu Zeng , Meiling Xu , Bin Shen , Wei Zhang , Yan Zhang , Weihong Wang , Kefeng Qin","doi":"10.1016/j.jcvp.2024.100191","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>For antiretroviral therapy (ART), drug combinations have been freely provided to people living with human immunodeficiency virus (PLWH) for treatment of acquired immunodeficiency syndrome (AIDS)in China. We have systematically analyzed the treatment results in Huzhou, Zhejiang Province.</div></div><div><h3>Methods</h3><div>Total 724 patients with HIV antibody positive from May 2005 to March 2023 at the age of 40.4±15.4 (15-82) years were treated with free provided drug combinations, including lamivudine (3TC), efavirenz (EFV) and tenofovir (TDF), or drugs at patient's own expense, includingbictegravir (BIC), emtricitabine (FTC) and tenofovir alafenamide (TAF). CD4+ T-cell count and viral load (VL) were detected before and after HAART treatment.</div></div><div><h3>Results</h3><div>Before and after HAART treatment, CD4+ T-cell count and viral load (VL) were measured. CD4+ T-cell count in 724 PLWH was from 269.2±178.9 to 453.8±243.3 cells/µl (<em>p</em>=0.0001), with 627(86.60%) cases increasing (221.0±204.6 cells/µl), 63(8.70%) decreasing (-96.0±84.1 cells/µl), 54(7.46%) cases no change. At the end of the treatment, 251(34.67%) cases were with CD4+ T-cell count>500.Viral load (VL)in 243 PLWHwas 14,474.4±62769.4 vs. 1,100.3±8513.1 copies/ml (<em>p</em>=0.0011), and with 181(74.49%) cases decreasing (-18,365.3±71,761.1 copies/ml), 14(5.76%) increasing (5,302.3±11,766.8 copies/ml), and 48 (19.75%) no change. Twenty-six patients died during the treatment period. There were no significant differences between results using free provided and paid drug combinations.</div></div><div><h3>Conclusion</h3><div>The free provided drug combinations increase CD4+ T-cell count and decrease viral load in PLWH, but about one-fourth of patients are considered as treatment failure. The improvement is needed for the HAART treatment.</div></div>","PeriodicalId":73673,"journal":{"name":"Journal of clinical virology plus","volume":"4 4","pages":"Article 100191"},"PeriodicalIF":1.6000,"publicationDate":"2024-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of clinical virology plus","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2667038024000164","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}

引用次数: 0

Abstract

Background

For antiretroviral therapy (ART), drug combinations have been freely provided to people living with human immunodeficiency virus (PLWH) for treatment of acquired immunodeficiency syndrome (AIDS)in China. We have systematically analyzed the treatment results in Huzhou, Zhejiang Province.

Methods

Total 724 patients with HIV antibody positive from May 2005 to March 2023 at the age of 40.4±15.4 (15-82) years were treated with free provided drug combinations, including lamivudine (3TC), efavirenz (EFV) and tenofovir (TDF), or drugs at patient's own expense, includingbictegravir (BIC), emtricitabine (FTC) and tenofovir alafenamide (TAF). CD4+ T-cell count and viral load (VL) were detected before and after HAART treatment.

Results

Before and after HAART treatment, CD4+ T-cell count and viral load (VL) were measured. CD4+ T-cell count in 724 PLWH was from 269.2±178.9 to 453.8±243.3 cells/µl (p=0.0001), with 627(86.60%) cases increasing (221.0±204.6 cells/µl), 63(8.70%) decreasing (-96.0±84.1 cells/µl), 54(7.46%) cases no change. At the end of the treatment, 251(34.67%) cases were with CD4+ T-cell count>500.Viral load (VL)in 243 PLWHwas 14,474.4±62769.4 vs. 1,100.3±8513.1 copies/ml (p=0.0011), and with 181(74.49%) cases decreasing (-18,365.3±71,761.1 copies/ml), 14(5.76%) increasing (5,302.3±11,766.8 copies/ml), and 48 (19.75%) no change. Twenty-six patients died during the treatment period. There were no significant differences between results using free provided and paid drug combinations.

Conclusion

The free provided drug combinations increase CD4+ T-cell count and decrease viral load in PLWH, but about one-fourth of patients are considered as treatment failure. The improvement is needed for the HAART treatment.

查看原文本刊更多论文

中国湖州艾滋病病毒感染者免费接受 HAART 治疗

背景在中国，人类免疫缺陷病毒感染者（PLWH）可免费接受抗逆转录病毒治疗（ART），以治疗获得性免疫缺陷综合征（AIDS）。我们对浙江省湖州市的治疗效果进行了系统分析。方法2005年5月至2023年3月，共收治724例HIV抗体阳性患者，年龄（40.4±15.4（15-82）岁，接受了免费提供的药物组合治疗，包括拉米夫定（3TC）、依非韦伦（EFV）和替诺福韦（TDF），或患者自费药物，包括比特拉韦（BIC）、恩曲他滨（FTC）和替诺福韦阿酚酰胺（TAF）。在 HAART 治疗前后，检测了 CD4+ T 细胞计数和病毒载量（VL）。结果在 HAART 治疗前后，检测了 CD4+ T 细胞计数和病毒载量（VL）。724 名 PLWH 的 CD4+ T 细胞计数从 269.2±178.9 cells/µl 升至 453.8±243.3 cells/µl（P=0.0001），其中 627 例（86.60%）增加（221.0±204.6 cells/µl），63 例（8.70%）减少（-96.0±84.1 cells/µl），54 例（7.46%）无变化。治疗结束时，251 例（34.67%）CD4+ T 细胞计数为 500。243 例 PLWH 的病毒载量（VL）为（14474.4±62769.4）拷贝数/毫升与（1100.3±8513.1）拷贝数/毫升（P=0.其中 181 例（74.49%）降低（-18,365.3±71,761.1 拷贝/毫升），14 例（5.76%）升高（5,302.3±11,766.8 拷贝/毫升），48 例（19.75%）无变化。26 名患者在治疗期间死亡。结论免费提供的药物组合可提高 PLWH 的 CD4+ T 细胞计数并降低病毒载量，但约四分之一的患者被视为治疗失败。HAART 治疗需要改进。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of clinical virology plus Infectious Diseases

CiteScore

2.20

自引率

0.00%

发文量

审稿时长

66 days